ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint744,924 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentBaselSOTIO Biotech AG
SOTIO Biotech AG Logo
Verified· 2 sources

SOTIO Biotech AG

Summary

About the company

The core activity of SOTIO is the development and research of oncological therapies, particularly in the field of biologics, such as antibody-drug conjugates (ADCs), immunocytokines and cell therapies. The company focuses on the development of drugs for the treatment of cancer and has built a pipeline of oncological programs driven by strategic licensing, M&A and internal discovery efforts.

AI-generated
Offering

Products & services

Industry:Research & DevelopmentPharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered6
Targeted cancer therapies
Targeted cancer therapies with first-in-class and best-in-class potential, developed as mono- and bispecific antibody-drug conjugates and a PD-1 cis-targeted IL-15 immunocytokine.
Immunocytokine platform
Immunocytokine platform for preferential activation of immune cells in the tumor microenvironment through targeted delivery of a cytokine agonist.
IL-15 Superagonist candidates
IL-15 Superagonist candidates for oncology, including Nanrilkefusp alfa and SOT201, developed to expand cytotoxic T cells and NK cells.
Antibody-drug conjugates (ADCs)
Antibody-drug conjugate programs and technology for solid tumors, including proprietary and partnered ADC development platforms and multiple oncology candidates.
ADC technology
ADC technology combining proprietary antibodies with conjugation and linker-payload platforms from collaboration partners to research, develop, manufacture and commercialize ADC products.
Comparisons

SOTIO Biotech AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank SOTIO Biotech AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of SOTIO Biotech AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Lichtstrasse 35
4056 Basel

At a glance

Legal form
Corporation
UID
CHE-354.429.802
Founded
2019 · 7 years
Last commercial register change
July 17, 2026
Employees
101 to 500

Knowledge

No knowledge articles yet

Once SOTIO Biotech AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started

Similar companies

FT
FoRx Therapeutics AG
Basel
VT
Vaderis Therapeutics AG
Basel
RG
RXcel GmbH
Basel
NA
NBE-Therapeutics AG
Basel
RS
Regeneron Switzerland GmbH
Basel
FA
FimmCyte AG
Basel
PS
PreClinical Safety (PCS) Consultants Ltd
Basel
IP
Ironwood Pharmaceuticals GmbH
Basel